Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation Journal Article


Authors: Uy, G. L.; Costa, L. J.; Hari, P. N.; Zhang, M. J.; Huang, J. X.; Anderson, K. C.; Bredeson, C. N.; Callander, N. S.; Cornell, R. F.; Perez, M. A.; Dispenzieri, A.; Freytes, C. O.; Gale, R. P.; Garfall, A.; Gertz, M. A.; Gibson, J; Hamadani, M; Lazarus, H. M.; Kalaycio, M. E.; Kamble, R. T.; Kharfan-Dabaja, M. A.; Krishnan, A. Y.; Kumar, S. K.; Kyle, R. A.; Landau, H. J.; Lee, C. H.; Maiolino, A; Marks, D. I.; Mark, T. M.; Munker, R; Nishihori, T; Olsson, R. F.; Ramanathan, M; Rodriguez, T. E.; Saad, A. A.; Savani, B. N.; Schiller, G. J.; Schouten, H. C.; Schriber, J. R.; Scott, E.; Seo, S; Sharma, M.; Ganguly, S; Stadtmauer, E. A.; Tay, J.; To, L. B.; Vesole, D. H.; Vogl, D. T.; Wagner, J. L.; Wirk, B; Wood, W. A.; D'Souza, A
Article Title: Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
Abstract: In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (0.5 x 109/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (20 x 109/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.Bone Marrow Transplantation advance online publication, 24 August 2015; doi:10.1038/bmt.2015.190.
Journal Title: Bone marrow transplantation
ISSN: 1476-5365; 0268-3369
Publisher: Unknown  
Date Published: 2015
Language: ENG
DOI/URL:
Notes: LR: 20150826; GR: U10 HL069294/HL/NHLBI NIH HHS/United States; GR: U24 CA076518/CA/NCI NIH HHS/United States; GR: UL1 TR000055/TR/NCATS NIH HHS/United States; JID: 8702459; NIHMS708096; PMCR: 2017/02/24 00:00; 2015/04/07 [received]; 2015/06/16 [revised]; 2015/07/10 [accepted]; aheadofprint
LUC Authors
Related LUC Article